In myeloid dendritic cells (DC)， deletion of the mechanistic target of rapamycin complex 2 (TORC2) results in an augmented pro-inflammatory phenotype and T cell stimulatory activity; however， the underlying mechanism has not been resolved. Here， we demonstrate that mouse bone marrow-derived TORC2-deficient myeloid DC (TORC2 DC) utilize an altered metabolic program， characterized by enhanced baseline glycolytic function compared to wild-type WT control (Ctrl) DC， increased dependence on glycolytic ATP production， elevated lipid content and higher viability following stimulation with LPS. In addition， TORC2 DC display an increased spare respiratory capacity (SRC) compared to WT Ctrl DC; this metabol... More
In myeloid dendritic cells (DC)， deletion of the mechanistic target of rapamycin complex 2 (TORC2) results in an augmented pro-inflammatory phenotype and T cell stimulatory activity; however， the underlying mechanism has not been resolved. Here， we demonstrate that mouse bone marrow-derived TORC2-deficient myeloid DC (TORC2 DC) utilize an altered metabolic program， characterized by enhanced baseline glycolytic function compared to wild-type WT control (Ctrl) DC， increased dependence on glycolytic ATP production， elevated lipid content and higher viability following stimulation with LPS. In addition， TORC2 DC display an increased spare respiratory capacity (SRC) compared to WT Ctrl DC; this metabolic phenotype corresponds with increased mitochondrial mass and mean mitochondrial DNA copy number， and failure of TORC2 DC mitochondria to depolarize following LPS stimulation. Our data suggest that the enhanced metabolic activity of TORC2 DC may be due to compensatory TORC1 pathway activity， namely increased expression of multiple genes upstream of Akt/TORC1 activity， including the integrin alpha IIb， protein tyrosine kinase 2/focal adhesion kinase， IL-7R and Janus kinase 1(JAK1)， and the activation of downstream targets of TORC1， including p70S6K， eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and CD36 (fatty acid translocase). These enhanced TORC1 pathway activities may culminate in increased expression of the nuclear receptor peroxisome proliferator-activated receptor γ (Pparγ) that regulates fatty acid storage， and the transcription factor sterol regulatory element-binding transcription factor 1 (Srebf1). Taken together， our data suggest that TORC2 may function to restrain TORC1-driven metabolic activity and mitochondrial regulation in myeloid DC.
